Development of a Potential Multilayered Biofunctional Dressing for Localized Postoperative Cancer Treatment: A Hybrid Approach Using 3D Printing and Electrospinning.
Saved in:
| Title: | Development of a Potential Multilayered Biofunctional Dressing for Localized Postoperative Cancer Treatment: A Hybrid Approach Using 3D Printing and Electrospinning. |
|---|---|
| Authors: | Bingol, Ayse Betul1 (AUTHOR) betul.bingol@std.yildiz.edu.tr, Karakas, Canan Yagmur2 (AUTHOR), Akkurt Yildirim, Meryem3 (AUTHOR), Insel, Mert Akın4 (AUTHOR), Zaman, Ali Can5 (AUTHOR), Oktay, Busra1 (AUTHOR), Ustundag, Cem Bulent1,6 (AUTHOR) |
| Source: | Macromolecular Materials & Engineering. Nov2025, Vol. 310 Issue 11, p1-15. 15p. |
| Subjects: | Surgical dressings, Oncologic surgery, Electrospinning, Pharmacokinetics, Amoxicillin, Doxorubicin, Ibuprofen, Three-dimensional printing |
| Abstract: | This study introduces a multilayered biofunctional tumor dressing designed for localized treatment after tumor resection. The system incorporates three therapeutic agents: doxorubicin (DOX) for anticancer action, amoxicillin (AMOX) for antibacterial protection, and ibuprofen (IBU) for anti‐inflammatory support. These drugs were loaded into polyvinyl alcohol (PVA) and polycaprolactone (PCL) matrices via a hybrid method combining 3D printing, electrospinning, and electrospraying. FTIR, SEM, and optical microscopy confirmed structural integrity. in vitro release at pH 7.4 and 37°C showed rapid DOX and AMOX release within 240 min, while IBU exhibited sustained release over 120 h. Mathematical modeling (zero‐order, first‐order, Higuchi, and Korsmeyer–Peppas) indicated diffusion‐driven, matrix‐controlled kinetics. Encapsulation efficiencies exceeded 98%, affirming fabrication reliability. Antibacterial tests showed stronger activity against Staphylococcus aureus than Escherichia coli. Cytotoxicity results demonstrated selective toxicity, with 42.86% viability in CCD1072‐Sk fibroblasts and lower survival in MCF‐7 (25.63%) and A549 (23.76%) cancer cells. This multifunctional dressing enables spatial and temporal control over drug release to effectively manage residual tumor cells, infection, and inflammation, offering a promising strategy for postoperative cancer therapy with minimized systemic side effects. [ABSTRACT FROM AUTHOR] |
| Copyright of Macromolecular Materials & Engineering is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | This study introduces a multilayered biofunctional tumor dressing designed for localized treatment after tumor resection. The system incorporates three therapeutic agents: doxorubicin (DOX) for anticancer action, amoxicillin (AMOX) for antibacterial protection, and ibuprofen (IBU) for anti‐inflammatory support. These drugs were loaded into polyvinyl alcohol (PVA) and polycaprolactone (PCL) matrices via a hybrid method combining 3D printing, electrospinning, and electrospraying. FTIR, SEM, and optical microscopy confirmed structural integrity. in vitro release at pH 7.4 and 37°C showed rapid DOX and AMOX release within 240 min, while IBU exhibited sustained release over 120 h. Mathematical modeling (zero‐order, first‐order, Higuchi, and Korsmeyer–Peppas) indicated diffusion‐driven, matrix‐controlled kinetics. Encapsulation efficiencies exceeded 98%, affirming fabrication reliability. Antibacterial tests showed stronger activity against Staphylococcus aureus than Escherichia coli. Cytotoxicity results demonstrated selective toxicity, with 42.86% viability in CCD1072‐Sk fibroblasts and lower survival in MCF‐7 (25.63%) and A549 (23.76%) cancer cells. This multifunctional dressing enables spatial and temporal control over drug release to effectively manage residual tumor cells, infection, and inflammation, offering a promising strategy for postoperative cancer therapy with minimized systemic side effects. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 14387492 |
| DOI: | 10.1002/mame.202500218 |
